{"id":1036525,"date":"2012-10-08T13:12:06","date_gmt":"2012-10-08T13:12:06","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/prana-biotechnology-revised-table-in-2012-annual-report.php"},"modified":"2024-08-17T15:57:06","modified_gmt":"2024-08-17T19:57:06","slug":"prana-biotechnology-revised-table-in-2012-annual-report","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/prana-biotechnology-revised-table-in-2012-annual-report.php","title":{"rendered":"Prana Biotechnology: Revised Table in 2012 Annual Report"},"content":{"rendered":"<p><p>      MELBOURNE, AUSTRALIA--(Marketwire - Oct 8, 2012) -      Prana Biotechnology Limited ( NASDAQ : PRAN      ) ( ASX : PBT ) today announced that it has identified the      below correction to a table lodged in the Company's Annual      Report on 28 September 2012.The table appears on page      45 on the notes to the financial statements in the annual      report.The correction related to 2012 \"Short-term      employee benefits\" and \"Post-employment benefits.\" The      revised table is attached.    <\/p>\n<p>      Finalisation of printing of the annual report is now underway      and Prana looks forward to the report being dispatched to all      shareholders who have nominated to receive a hard copy of the      report in the near future.The revised report will also      be released on the ASX at that same time.    <\/p>\n<p>      About Prana Biotechnology Limited Prana      Biotechnology was established to commercialize research into      age-related neurodegenerative disorders. The Company was      incorporated in 1997 and listed on the Australian Securities      Exchange in March 2000 and listed on NASDAQ in September      2002.Researchers at prominent international      institutions including The University of Melbourne, The      Mental Health Research Institute (Melbourne) and      Massachusetts General Hospital, a teaching hospital of      Harvard Medical School, contributed to the discovery of      Prana's technology.    <\/p>\n<p>      For further information please visit the Company's web site      at       <a href=\"http:\/\/www.pranabio.com\" rel=\"nofollow\">http:\/\/www.pranabio.com<\/a>.    <\/p>\n<\/p>\n<p>See the rest here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/prana-biotechnology-revised-table-2012-130100987.html;_ylt=A2KJjbwS0XJQbj0AG4f_wgt.\" title=\"Prana Biotechnology: Revised Table in 2012 Annual Report\" rel=\"noopener\">Prana Biotechnology: Revised Table in 2012 Annual Report<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> MELBOURNE, AUSTRALIA--(Marketwire - Oct 8, 2012) - Prana Biotechnology Limited ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that it has identified the below correction to a table lodged in the Company's Annual Report on 28 September 2012.The table appears on page 45 on the notes to the financial statements in the annual report.The correction related to 2012 \"Short-term employee benefits\" and \"Post-employment benefits.\" The revised table is attached. Finalisation of printing of the annual report is now underway and Prana looks forward to the report being dispatched to all shareholders who have nominated to receive a hard copy of the report in the near future.The revised report will also be released on the ASX at that same time. About Prana Biotechnology Limited Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/prana-biotechnology-revised-table-in-2012-annual-report.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036525","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036525"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036525"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}